Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
This study has been completed.
Study NCT00002222   Information provided by NIH AIDS Clinical Trials Information Service
First Received: November 2, 1999   Last Updated: June 23, 2005   History of Changes

November 2, 1999
June 23, 2005
 
 
 
 
Complete list of historical versions of study NCT00002222 on ClinicalTrials.gov Archive Site
 
 
 
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
An Open Label Study of the Safety and Tolerability of Valganciclovir, an Oral Prodrug of Ganciclovir, for the Treatment of Cytomegalovirus Retinitis in Subjects With AIDS

The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.

Patients receive valganciclovir twice a day for 21 days as induction therapy then daily as maintenance therapy. Patients are encouraged to remain on study for at least 3 months and will remain until common study closure.

 
Interventional
Treatment, Open Label, Safety Study
  • Cytomegalovirus Retinitis
  • HIV Infections
Drug: Valganciclovir
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Completed
200
 
 

Inclusion Criteria

Concurrent Medication:

Allowed with caution:

  • Acyclovir.
  • Famciclovir.
  • Valaciclovir.
  • Imipenem-cilastatin.
  • Myelosuppressive agents.

Patients must have:

  • HIV infection with CMV retinitis.
  • Minimum of 4 weeks prior treatment with ganciclovir, foscarnet, or cidofovir.
  • Intraocular implant in either or both eyes, as long as CMV retinitis is active in one eye, upon approval by Roche.

Exclusion Criteria

Co-existing Condition:

Patients with any of the following symptoms of conditions are excluded:

  • Active extraocular CMV disease.
  • Severe uncontrolled diarrhea or evidence of malabsorption.

Concurrent Medication:

Excluded:

  • Foscarnet.
  • Cidofovir.
  • CMV hyperimmune globulin.
  • Probenecid.

Patients with the following prior conditions are excluded:

  • Ocular media opacities (corneal, aqueous, lens, or vitreous) preventing ophthalmologic retinal assessment.
  • Simultaneous participation in another study (unless approved by Roche).

Required:

  • A minimum of 4 weeks treatment with ganciclovir, foscarnet, or cidofovir.
  • Approval required for prior use of investigational anti-CMV agents.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002222
 
268B
Hoffmann-La Roche
 
 
NIH AIDS Clinical Trials Information Service
April 1999

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP